Pharmala Biotech Holdings Inc. (CSE: MDMA), a company focused on research, development and manufacturing of MDMA and similar class molecules, has registered a trademark for its clinical-grade, Good Manufacturing Practice MDMA product, to be available as “Laneo MDMA.”
The decision makes Pharmala the only publicly traded company to have developed a full manufacturing value series for MDMA to date, encompassing GMP manufacturing of Active Pharmaceutical Ingredients (API) and drug product formulation.
The company defines itself as a "regulatory first" organization, which translates to the principle …
Full story available on Benzinga.com
